Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) rose 1.7% on Wednesday . The company traded as high as $47.20 and last traded at $47.20. Approximately 15,299 shares were traded during trading, an increase of 106% from the average daily volume of 7,422 shares. The stock had previously closed at $46.40.
Ascentage Pharma Group International Stock Up 0.4%
The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24. The stock has a fifty day simple moving average of $40.17 and a two-hundred day simple moving average of $28.49.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AAPG. Chevy Chase Trust Holdings LLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $227,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Tema Etfs LLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $610,000. Finally, Monashee Investment Management LLC purchased a new position in Ascentage Pharma Group International during the 1st quarter valued at about $3,511,000.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Stories
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access